|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The histomolecular profile appears to be different from that of supratentorial gliomas, with no IDH1/2 gene mutations and only 1 case with a classic profile of de novo glioblastoma.
|
29809131 |
2019 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, there are limited prognostic markers of glioblastoma including IDH1, ATRX, MGMT, PTEN, EGFRvIII, and others.
|
29372493 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, having access to IDH1 wild-type glioblastoma of patients with exceptionally long recurrence free survival (RFS), we decided to compare their mutational and gene expression profile to groups of IDH1 wild-type glioblastoma of patients with shorter RFS, by using NGS technology.
|
29844869 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.
|
28988652 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, given that the effect of mutant IDH1 was not recapitulated in glioblastoma cells, the enhancement of JQ1 sensitivity by IDH1 mutation seems to be specific for ICC cells.
|
30156013 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
No survival difference was noted between patients with glioblastoma harboring the SNP and patients with IDH wild type glioblastoma.
|
29423539 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association of a SNP known to confer risk for IDH1/2 mutant glioma and higher prevalence of IDH1/2 mutation within younger individuals 18-53 suggests that more younger individuals may present initially with 'secondary glioblastoma.'
|
30152087 |
2018 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Three hundred patients with newly diagnosed WHO 2007 grades II-IV gliomas with 18F-FET-PET imaging at diagnosis were grouped into 4 subgroups (IDH1/2 mut-1p/19q codel; IDH1/2 mut-1p/19q non-codel; IDH1/2 wildtype WHO grade II and III tumors; and glioblastoma).
|
29016996 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GPR158 promotes glioma stem cell differentiation and induces apoptosis and is highest expressed in the cerebral cortex and in oligodendrogliomas, lower in IDH mutant astrocytomas and lowest in the most malignant form of glioma, IDH wild-type glioblastoma.
|
29720725 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
• Significant correlation exists between radiological parameters such as volumetric and ADC values and major genomic profiles such as IDH mutation and ATRX loss status • Radiological parameters such as the ADC value were feasible predictors of glioblastoma patients' prognosis • Imaging features can predict major genomic profiles of the tumours and the prognosis of glioblastoma patients.
|
29721688 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A novel molecular recursive partitioning analysis classification has recently been reported integrating the MGMT promoter methylation (MGMTmeth) and IDH1 mutation (IDH1mut) status for glioblastoma (GBM-molRPA) patients treated with temozolomide-based chemoradiation.
|
30236994 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hsa_circ_0008344, among the top differentially expressed circRNAs, was significantly upregulated in IDH1 wild-type glioblastoma.
|
29687495 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed The Cancer Genome Atlas dataset (TCGA) and identified a small group of IDH-mutant, WHO grade II-III astrocytomas (n = 14) with an unexpectedly poor prognosis characterized by a rapid progression to glioblastoma and death within 3 years of the initial diagnosis.
|
29741737 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We excluded glioblastoma-like tumors (7a10d subgroup) and derived a gene expression signature distinguishing histologically classified oligodendrogliomas with concurrent 1p/19q co-deletion and IDH mutation (1p/19q subgroup) from those with predominant IDH mutation alone (IDHme subgroup).
|
29631562 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The metabolic and bioenergetic features were identified in glioma cells using wild-type and genetically engineered IDH1-mutant glioblastoma cell lines by metabolic analyses with Seahorse, protein expression studies and liquid chromatography-mass spectrometry.
|
30404651 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To confirm this mutation's role in GSCs, the IDH1-R132H in GSCs isolated from glioblastoma patients with IDH1 mutations was overexpressed by using lentiviral constructs in vitro, and then the proliferation, differentiation, apoptosis, migration and invasion of the transfected GSCs were explored.
|
29115585 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential expression of circRNAs may be associated with IDH-wt glioblastoma development and progression, and these circRNAs can be identified as biomarkers for prognosis prediction and targets for treatment.
|
29920451 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The pathologic diagnosis was glioblastoma with isocitrate dehydrogenase 1 (IDH-1) wild type arising in the left temporal region of the brain, penetrating the dura mater and propagating to the middle fossa with enlargement of the foramen rotundum.
|
29277589 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma.
|
30426720 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Low-grade gliomas (WHO II/III) had lower xCT expression than glioblastoma (p = 0.001), and tumors without IDH1 R132H mutation tended to have higher xCT levels (p = 0.07).
|
29404978 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Characterization of diverse immune responses will facilitate patient stratification and improve personalized immunotherapy in the future.<b>Significance:</b> This study utilizes a computational approach to characterize the immune environments in glioblastoma and shows that glioblastoma immune microenvironments can be classified into three major subgroups, which are linked to typical glioblastoma alterations such as IDH mutation, NF1 inactivation, and CDK4-MARCH9 locus amplification.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/19/5574/F1.large.jpg <i></i>.
|
29921698 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutant isocitrate dehydrogenase 1 (IDH1) is an attractive therapeutic target for the treatment of various cancers such as AML, glioma, and glioblastoma.
|
30034612 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The findings of the current study demonstrate presence of the IDH1 R132H mutation in primary human glioblastoma cell lines with upregulated HIF-1α expression, downregulating c-MYC activity and resulting in a consequential decrease in miR-20a, which is responsible for cell proliferation and resistance to standard temozolomide treatment.
|
29625108 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
After chemoradiation with concomitant and adjuvant temozolomide, 21 IDH wild-type glioblastoma patients at first progression (age range, 33-75 years; MGMT promoter unmethylated, 81%) were treated with BEV/LOM.
|
29982845 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> High radiation doses to ipsilateral NSC and contralateral SVZ could have a negative impact on overall survival in IDH-wild-type glioblastoma population.
|
30338243 |
2018 |